Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLLLina van der Straten, Mark‐David Levin, Julie Dubois et al.|Blood|2023Cited by 27
Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus VenetoclaxLaura Eurelings, Mark‐David Levin, Emelie Curovic Rotbain et al.|Blood|2024Cited by 1